GenFleet Therapeutics (Shanghai) Inc banner

GenFleet Therapeutics (Shanghai) Inc
HKEX:2595

Watchlist Manager
GenFleet Therapeutics (Shanghai) Inc Logo
GenFleet Therapeutics (Shanghai) Inc
HKEX:2595
Watchlist
Price: 25.04 HKD -7.53% Market Closed
Market Cap: HK$9.3B

Intrinsic Value

The intrinsic value of one GenFleet Therapeutics (Shanghai) Inc stock under the Base Case scenario is 2.86 HKD. Compared to the current market price of 25.04 HKD, GenFleet Therapeutics (Shanghai) Inc is Overvalued by 89%.

Intrinsic Value
2.86 HKD
Overvaluation 89%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
GenFleet Therapeutics (Shanghai) Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about GenFleet Therapeutics (Shanghai) Inc?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is GenFleet Therapeutics (Shanghai) Inc valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for GenFleet Therapeutics (Shanghai) Inc.

Explain Valuation
Alternatives to GenFleet Therapeutics (Shanghai) Inc

Fundamental Analysis

Financials

Revenue & Expenses Breakdown
GenFleet Therapeutics (Shanghai) Inc

Efficiency

Earnings Waterfall
GenFleet Therapeutics (Shanghai) Inc

Wall St
Price Targets

Dividends

GenFleet Therapeutics (Shanghai) Inc
does not pay dividends
Shareholder Yield

Competitive Landscape

What is the Intrinsic Value of one GenFleet Therapeutics (Shanghai) Inc stock?

The intrinsic value of one GenFleet Therapeutics (Shanghai) Inc stock under the Base Case scenario is 2.86 HKD.

Is GenFleet Therapeutics (Shanghai) Inc stock undervalued or overvalued?

Compared to the current market price of 25.04 HKD, GenFleet Therapeutics (Shanghai) Inc is Overvalued by 89%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett